Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxafuramine is a synthetic stimulant and anorectic drug belonging to the oxazoline chemical class. It is structurally related to aminorex and 4-methylaminorex. Developed in the 1960s, oxafuramine was investigated for its potential as an appetite suppressant. Its mechanism of action involves sympathomimetic activity, likely through the modulation of monoamine transporters, leading to increased levels of norepinephrine and dopamine in the synaptic cleft. Despite its pharmacological potential, oxafuramine was never approved for clinical use or widely marketed, and it remains primarily a compound of historical and toxicological interest.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxafuramine.